AJICAP® Antibody-Drug Conjugate Manufacturing Technology Contributes to Enhanced Efficacy of Antibody Drugs TOKYO, May 6, 2025 /PRNewswire/ -- Ajinomoto Co., Inc. (President: Shigeo Nakamura, Headquarters: Chuo-ku, Tokyo, hereinafter referred to as "Ajinomoto") has been conducting joint...
Read More Details
Finally We wish PressBee provided you with enough information of ( Successful Extension of Nucleic Acid Aptamer Pharmacokinetics in Joint Research by Ajinomoto Co., Inc. and RIBOMIC Inc. )
Also on site :
- Kremlin comments on ceasefire plans after Ukrainian drone strikes
- India-Pakistan deadly fighting forces airlines to re-route, cancel flights
- Bitcoin consolidates above a key level as all-time highs continue to be in sight